Hansen Bo Jesper
Pharma
Sustainable Resource Engineering
Italy
Biography
David Fischer joined Charles River through the acquisition of BioFocus from Galapagos, and has since taken a leadership role on a number of early-stage drug discovery programs in rare and orphan disease indications, including cystic fibrosis, Huntington’s Disease, ALS, Usher III Syndrome, and DMD. He brings expertise in complex and primary cell-based assays, including iSPC and hESC stem cells models.
Research Interest
Pharma
